LABP
Price:
$22.93
Market Cap:
$71.68M
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therape...[Read more]
Industry
Biotechnology
IPO Date
2021-02-04
Stock Exchange
NASDAQ
Ticker
LABP
According to Landos Biopharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.73. This represents a change of 210.31% compared to the average of -1.85 of the last 4 quarters.
The mean historical PE Ratio of Landos Biopharma, Inc. over the last ten years is -17.17. The current -5.73 PE Ratio has changed 3.24% with respect to the historical average. Over the past ten years (40 quarters), LABP's PE Ratio was at its highest in in the June 2021 quarter at 23.71. The PE Ratio was at its lowest in in the December 2019 quarter at -27.89.
Average
-17.17
Median
-10.51
Minimum
-45.87
Maximum
-0.53
Discovering the peaks and valleys of Landos Biopharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 97.66%
Maximum Annual PE Ratio = -0.53
Minimum Annual Increase = -89.52%
Minimum Annual PE Ratio = -45.87
Year | PE Ratio | Change |
---|---|---|
2023 | -1.05 | 97.66% |
2022 | -0.53 | -89.52% |
2021 | -5.05 | -68.35% |
2020 | -15.97 | -53.77% |
2019 | -34.54 | -24.70% |
The current PE Ratio of Landos Biopharma, Inc. (LABP) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.21
5-year avg
-11.43
10-year avg
-17.17
Landos Biopharma, Inc.’s PE Ratio is less than eFFECTOR Therapeutics, Inc. (-0.00), less than Apexigen, Inc. (-0.24), less than Navidea Biopharmaceuticals, Inc. (0.03), less than Angion Biomedica Corp. (-0.46), less than Oncorus, Inc. (0), less than Apollomics, Inc. (-0.04), less than Cardio Diagnostics Holdings, Inc. (-0.15), less than TransCode Therapeutics, Inc. (-0.79), less than NexImmune, Inc. (-0.38), less than Xenetic Biosciences, Inc. (-0.02), less than null (-1.55),
Company | PE Ratio | Market cap |
---|---|---|
-0.00 | $941.00 | |
-0.24 | $9.57M | |
0.03 | $100.08K | |
-0.46 | $30.11M | |
0 | $0 | |
-0.04 | $9.98M | |
-0.15 | $10.73M | |
-0.79 | $6.64M | |
-0.38 | $488.13K | |
-0.02 | $6.33M | |
-1.55 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Landos Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Landos Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Landos Biopharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Landos Biopharma, Inc. (LABP)?
What is the highest PE Ratio for Landos Biopharma, Inc. (LABP)?
What is the 3-year average PE Ratio for Landos Biopharma, Inc. (LABP)?
What is the 5-year average PE Ratio for Landos Biopharma, Inc. (LABP)?
How does the current PE Ratio for Landos Biopharma, Inc. (LABP) compare to its historical average?